Sometimes the most important decision is when to refer
Community oncologists manage an extraordinary amount of cancer care. But as oncology becomes more specialized, there are some treatments that just can't be delivered in every practice. Cellular therapies, complex procedures and clinical trials may require specialized teams, infrastructure and centers with significant experience.
That creates a clinical decision we don't talk about enough: When should I refer?
Increasingly, the answer is: before the patient needs the treatment.
Referral shouldn't begin when you've run out of options
The traditional model is straightforward: treat the patient locally, move through the available therapies, and if those stop working, refer to an academic or tertiary center for something more specialized.
For some cancers and treatments, that sequence may be too late.
Consider a therapy that requires evaluation at a specialized center, a surgical procedure to harvest cells, manufacturing, conditioning and then treatment. The patient can't decide on Monday that they want the therapy and receive it on Friday, simply because there may be weeks between referral and treatment.
Meanwhile, the cancer is still progressing.
A patient who was a reasonable candidate when second-line treatment began may no longer be one by the time third-line treatment fails. The referral window can close.
Think about second line while you're prescribing first line
This may require a different way of thinking about treatment sequencing. Starting first-line therapy shouldn't only trigger the question: what do I do if this doesn't work? It should also trigger: if this patient eventually needs specialized treatment, when do I need to get that process started?
Those aren't the same question. Referral doesn't necessarily mean changing treatment today. It can mean establishing the relationship, assessing eligibility and understanding the options while the patient is still doing well.
Then, if the disease progresses, the next step has already been anticipated. In other words, referral can be integrated into treatment planning rather than left as a last resort.
Performance status is an asset
Oncologists spend a lot of time thinking about preserving organ function and marrow reserve. We should probably think about preserving eligibility in much the same way.
A patient may be eligible for a specialized therapy today and too sick to receive it several weeks or months from now.
Every additional treatment has consequences. Toxicity accumulates. Performance status can decline. Disease burden can increase.
Sometimes another cycle buys useful disease control, but sometimes it consumes part of a limited window in which another option remains possible. Knowing the difference is clinical judgment.
The community oncologist has a vital role
There is also a practical reason referrals can be difficult. Patients often don't want to leave the physician who has been caring for them. They may live hours from an ATC. Their loved ones, jobs and support systems are at home. And community oncologists may reasonably wonder what happens to the patient after they make the referral.
A better model is shared care. The ATC handles the parts of treatment requiring specialized expertise and infrastructure. The community oncologist remains involved where appropriate and resumes more of the patient's care when it can safely move closer to home.
This relationship should be designed into the referral pathway.
The question shouldn't be: community oncologist or academic center. Instead, it should be which parts of this patient's care are best delivered where?
We need better referral algorithms
Treatment algorithms usually focus on drugs: First line → progression → second line → progression → third line.
But increasingly, that's incomplete. A useful clinical algorithm should also tell physicians:
When should I start thinking about referral?
What makes this patient eligible?
What needs to happen before treatment?
How long could the process take?
What changes should trigger an earlier referral?
What can I continue managing locally?
When should the patient come back to my practice?
These details can determine whether a treatment remains available at all.
The best referral may be the one that feels early
Community oncology has enormous advantages. Patients can receive sophisticated cancer care close to home, often from physicians who have treated them for years.
Centers of excellence have different advantages: concentrated expertise, specialized infrastructure, clinical trials and therapies that can't be offered everywhere.
Patients should be able to benefit from both options.
The goal isn't to send every patient to a tertiary center. It's to recognize the patients who may eventually need one, while there is still time.
Because in modern oncology, knowing when to refer may be just as important as knowing what to prescribe next.